BridgeBio Oncology Therapeutics, Inc.
BBOT
$7.40
-$0.29-3.77%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -154.10M | -134.04M | -114.93M | -87.50M | -80.89M |
| Total Depreciation and Amortization | 742.00K | 610.00K | 468.00K | 339.00K | 210.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.96M | 13.11M | 10.45M | 2.02M | 2.82M |
| Change in Net Operating Assets | 7.18M | 6.43M | 17.32M | 4.24M | 12.09M |
| Cash from Operations | -130.21M | -113.89M | -86.70M | -80.90M | -65.76M |
| Capital Expenditure | -468.00K | -606.00K | -543.00K | -414.00K | -197.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -226.98M | 73.93M | 91.66M | 54.00M | -107.36M |
| Cash from Investing | -227.45M | 73.33M | 91.12M | 53.59M | -107.55M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 373.92M | 373.50M | 373.51M | 52.00K | 382.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 22.22M | 22.22M | 22.22M | 22.22M | 199.26M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -12.04M | -12.32M | -11.69M | -3.67M | -404.00K |
| Cash from Financing | 384.10M | 383.40M | 384.04M | 18.60M | 199.24M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 26.44M | 342.84M | 388.46M | -8.71M | 25.92M |